Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | September 05, 2023 | September 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Unicycive Therapeutics, Inc.
Report date September 05, 2023 · Filed September 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2033-09-05 | Direct | 123,775 |
Reported balance
After 2023-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-05 · Grant · Acquired 112,147 · Balance 123,775 F1: 37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2026-12-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-12-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2028-12-14 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2030-01-27 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.96 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 175,000 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
| Equity Appreciation Rights UnitSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2024-12-16 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-09 · Disposition to issuer · Disposed 250 · Balance 0 F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award.
F2: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2023 Filed Sep 7, 2023 16:32 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 112,147 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001213900-23-075010 · ownership.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,775 Underlying: Common Stock · 112,147 shares Expires 2033-09-05 F1 · derivative.exercise_date: 37,382 options vest on June 26, 2024, 37,382 options vest on June 26, 2025 and 37,383 vest on June 26, 2026. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerEquity Appreciation Rights Unit · Derivative | 250 | $3.50 Strike: $6.00 | $875.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 6 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 250 shares Expires 2024-12-16 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 175,000 | $5.54 Strike: $3.96 | $969,500.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 5 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 175,000 shares Expires 2031-01-08 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $5.16 Strike: $4.34 | $516,000.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 4 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2030-01-27 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $7.03 Strike: $2.47 | $351,500.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 3 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-12-14 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | $5.86 Strike: $3.64 | $879,000.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 2 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 150,000 shares Expires 2027-12-08 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:41 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $4.84 Strike: $4.66 | $484,000.00 |
DisclosureSEC source: 0001104659-21-136410 · tm2131118-9_4seq1.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2026-12-15 F2 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR. F1 · derivative.exercise_date: In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:23 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001593968-21-000118 · primary_01.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common stock, par value $0.001 · 175,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 8, 2021, the date of grant. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 16:18 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001593968-20-000225 · primary_01.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · Executive Vice President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock, par value $0.001 · 100,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 27, 2020, the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 10:10 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantOption (right to buy) · Derivative | 50,000 | $2.47 Strike: $2.47 | $123,500.00 |
DisclosureSEC source: 0001593968-18-001603 · primary_01.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · Executive Vice President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-12-14 F1 · balance_after: Only represents derivative securities of this class. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 16:10 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001593968-17-001353 · primary_01.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · Executive Vice President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock, par value $0.001 · 150,000 shares Expires 2027-12-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 20:23 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $4.66 Strike: $4.66 | $466,000.00 |
DisclosureSEC source: 0001593968-16-001350 · primary_01.xml · derivative · entry 1 Ryan John L · CIK 0001679825 · Executive Vice President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2026-12-15 F1 · derivative.exercise_date: The option becomes vested and exercisable in two equal annual installments over 2 years from December 15, 2016, the date of grant. F2 · balance_after: Only represents derivative securities of this class. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.